Literature DB >> 18200575

Determination of terephthalic acid isopropylamide in urine with a liquid chromatography/mass spectrometry (LC/MS) method.

F Baumann1, C Mauz-Körholz, D Clauss, S Borrmann, A Giannis, N Merkel, D Körholz, R Preiss.   

Abstract

A sensitive and simple liquid chromatography/mass spectrometry (LC/MS) method was developed for the determination of terephthalic acid isopropylamide, the final metabolite of procarbazine in human urine. A solid-phase extraction with C(18) cartridges was used followed by LC/MS with a single mass spectrometer (SSQ 7000 from Finnigan). Terephthalic acid isobutylamide was the internal standard. The quantification limit was 30 ng/mL in urine (6 x noise). This assay was applied for drug monitoring of terephthalic acid isopropylamide in urine after oral administration of procarbazine in children and adolescents with Hodgkin lymphomas. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18200575      PMCID: PMC6649020          DOI: 10.1002/jcla.20213

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  12 in total

1.  SOME PHARMACOLOGIC PROPERTIES OF A NEW ANTITUMOR AGENT, N-ISOPROPYL-ALPHA-(2-METHYLHYDRAZINO)-P-TOLUAMIDE, HYDROCHLORIDE (NSC-77213).

Authors:  V T OLIVERIO; C DENHAM; V T DEVITA; M G KELLY
Journal:  Cancer Chemother Rep       Date:  1964-11

2.  [ON THE METABOLISM OF A CYTOSTATIC METHYLHYDRAZINE DERIVATIVE (NATULAN)].

Authors:  J RAAFLAUB; D E SCHWARTZ
Journal:  Experientia       Date:  1965-01-15

Review 3.  Metabolism of hydrazine anti-cancer agents.

Authors:  D J Tweedie; J M Erikson; R A Prough
Journal:  Pharmacol Ther       Date:  1987       Impact factor: 12.310

4.  High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: the German-Austrian multicenter trial DAL-HD-90. The German-Austrian Pediatric Hodgkin's Disease Study Group.

Authors:  G Schellong; R Pötter; J Brämswig; W Wagner; F J Prott; W Dörffel; D Körholz; G Mann; B Rath; A Reiter; G Weissbach; M Riepenhausen; M Thiemann; E W Schwarze
Journal:  J Clin Oncol       Date:  1999-12       Impact factor: 44.544

5.  Metabolic activation of procarbazine.

Authors:  R J Weinkam; D A Shiba
Journal:  Life Sci       Date:  1978-03       Impact factor: 5.037

6.  Plasma kinetics of procarbazine and azo-procarbazine in humans.

Authors:  Rainer Preiss; Frank Baumann; Ralf Regenthal; Michael Matthias
Journal:  Anticancer Drugs       Date:  2006-01       Impact factor: 2.248

7.  Procarbazine in haematology: an old drug with a new life?

Authors:  M Massoud; J P Armand; V Ribrag
Journal:  Eur J Cancer       Date:  2004-09       Impact factor: 9.162

Review 8.  N-methyl antitumour agents. A distinct class of anticancer drugs?

Authors:  D Newell; A Gescher; S Harland; D Ross; C Rutty
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

9.  Quantitative analysis of procarbazine, procarbazine metabolites and chemical degradation products with application to pharmacokinetic studies.

Authors:  D A Shiba; R J Weinkam
Journal:  J Chromatogr       Date:  1982-05-14

10.  Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.

Authors:  Volker Diehl; Jeremy Franklin; Michael Pfreundschuh; Bernd Lathan; Ursula Paulus; Dirk Hasenclever; Hans Tesch; Richard Herrmann; Bernd Dörken; Hans-Konrad Müller-Hermelink; Eckhardt Dühmke; Markus Loeffler
Journal:  N Engl J Med       Date:  2003-06-12       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.